Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPIC
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from th...
| Autori principali: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Journal article |
| Lingua: | English |
| Pubblicazione: |
Wiley
2019
|
| _version_ | 1826290296963465216 |
|---|---|
| author | Schmidt, J Fensom, G Rinaldi, S Scalbert, A Appleby, P Achaintre, D Gicquiau, A Gunter, M Ferrari, P Kaaks, R Kühn, T Boeing, H Trichopoulou, A Karakatsani, A Peppa, E Palli, D Sieri, S Tumino, R Bueno-De-Mesquita, B Agudo, A Sánchez, M Chirlaque, M Ardanaz, E Larrañaga, N Perez-Cornago, A Assi, N Riboli, E Tsilidis, K Key, T Travis, R |
| author_facet | Schmidt, J Fensom, G Rinaldi, S Scalbert, A Appleby, P Achaintre, D Gicquiau, A Gunter, M Ferrari, P Kaaks, R Kühn, T Boeing, H Trichopoulou, A Karakatsani, A Peppa, E Palli, D Sieri, S Tumino, R Bueno-De-Mesquita, B Agudo, A Sánchez, M Chirlaque, M Ardanaz, E Larrañaga, N Perez-Cornago, A Assi, N Riboli, E Tsilidis, K Key, T Travis, R |
| author_sort | Schmidt, J |
| collection | OXFORD |
| description | Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow‐up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. |
| first_indexed | 2024-03-07T02:41:59Z |
| format | Journal article |
| id | oxford-uuid:aac124c6-9ec4-4cd7-91e2-c8541f607fba |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:41:59Z |
| publishDate | 2019 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:aac124c6-9ec4-4cd7-91e2-c8541f607fba2022-03-27T03:17:29ZPatterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPICJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:aac124c6-9ec4-4cd7-91e2-c8541f607fbaEnglishSymplectic Elements at OxfordWiley2019Schmidt, JFensom, GRinaldi, SScalbert, AAppleby, PAchaintre, DGicquiau, AGunter, MFerrari, PKaaks, RKühn, TBoeing, HTrichopoulou, AKarakatsani, APeppa, EPalli, DSieri, STumino, RBueno-De-Mesquita, BAgudo, ASánchez, MChirlaque, MArdanaz, ELarrañaga, NPerez-Cornago, AAssi, NRiboli, ETsilidis, KKey, TTravis, RMetabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow‐up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. |
| spellingShingle | Schmidt, J Fensom, G Rinaldi, S Scalbert, A Appleby, P Achaintre, D Gicquiau, A Gunter, M Ferrari, P Kaaks, R Kühn, T Boeing, H Trichopoulou, A Karakatsani, A Peppa, E Palli, D Sieri, S Tumino, R Bueno-De-Mesquita, B Agudo, A Sánchez, M Chirlaque, M Ardanaz, E Larrañaga, N Perez-Cornago, A Assi, N Riboli, E Tsilidis, K Key, T Travis, R Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPIC |
| title | Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPIC |
| title_full | Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPIC |
| title_fullStr | Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPIC |
| title_full_unstemmed | Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPIC |
| title_short | Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPIC |
| title_sort | patterns in metabolite profile are associated with risk of more aggressive prostate cancer a prospective study of 3 057 matched case control sets from epic |
| work_keys_str_mv | AT schmidtj patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT fensomg patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT rinaldis patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT scalberta patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT applebyp patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT achaintred patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT gicquiaua patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT gunterm patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT ferrarip patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT kaaksr patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT kuhnt patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT boeingh patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT trichopouloua patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT karakatsania patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT peppae patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT pallid patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT sieris patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT tuminor patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT buenodemesquitab patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT agudoa patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT sanchezm patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT chirlaquem patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT ardanaze patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT larranagan patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT perezcornagoa patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT assin patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT ribolie patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT tsilidisk patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT keyt patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic AT travisr patternsinmetaboliteprofileareassociatedwithriskofmoreaggressiveprostatecanceraprospectivestudyof3057matchedcasecontrolsetsfromepic |